Seroprevalence of Sars-Cov-2 Antibody Among Urban Iranian Population: Findings From the Second Large Population-Based Cross-Sectional Study

Seroprevalence of Sars-Cov-2 Antibody Among Urban Iranian Population: Findings From the Second Large Population-Based Cross-Sectional Study Publisher Pubmed

Zamani M¹ ; Poustchi H² ; Mohammadi Z² ; Dalvand S² ; Sharafkhah M² ; Motevalian SA^{3, 4} ; Eslami S⁵ ; Emami A⁶ ; Somi MH⁷ ; Yazdanicharati J⁸ ; Saki N⁹ ; Karami M^{10, 11} ; Najafi F¹² ; Mohebbi I¹³ Show All Authors

Zamani M¹
Poustchi H²
Mohammadi Z²
Dalvand S²
Sharafkhah M²
Motevalian SA^{3, 4}
Eslami S⁵
Emami A⁶
Somi MH⁷
Yazdanicharati J⁸
Saki N⁹
Karami M^{10, 11}
Najafi F¹²
Mohebbi I¹³
Veisi N¹⁴
Hormati A^{15, 16}
Pourfarzi F¹⁷
Ghadimi R¹⁸
Ansarimoghaddam A¹⁹
Sharifi H²⁰
Roshandel G²¹
Mansourghanaei F²²
Joukar F²³
Shayanrad A²
Eghtesad S²
Niavarani A²⁴
Delavari A²⁴
Kaveh S²
Feizesani A²
Markarian M¹
Shafighian F²⁴
Sadjadi A²⁴
Darvishian M²⁵
Malekzadeh R^{1, 24}

Source: BMC Public Health Published:2022

Abstract

Background: The first large serosurvey in Iran found a SARS-CoV-2 antibody seroprevalence of 17.1% among the general population in the first wave of the epidemic by April, 2020. The purpose of the current study was to assess the seroprevalence of COVID-19 infection among Iranian general population after the third wave of the disease. Methods: This population-based cross-sectional study was conducted on 7411 individuals aged ≥10 years old in 16 cities across 15 provinces in Iran between January and March, 2021. We randomly sampled individuals registered in the Iranian electronic health record system based on their national identification numbers and invited them by telephone to a healthcare center for data collection. Presence of SARS-CoV-2-specific IgG and IgM antibodies was assessed using the SARS-CoV-2 ELISA kits. The participants were also asked about their recent COVID-19-related symptoms, including cough, fever, chills, sore throat, headache, dyspnea, diarrhea, anosmia, conjunctivitis, weakness, myalgia, arthralgia, altered level of consciousness, and chest pain. The seroprevalence was estimated after adjustment for population weighting and test performance. Results: The overall population-weighted seroprevalence adjusted for test performance was 34.2% (95% CI 31.0-37.3), with an estimated 7,667,874 (95% CI 6,950,412-8,362,915) infected individuals from the 16 cities. The seroprevalence varied between the cities, from the highest estimate in Tabriz (39.2% [95% CI 33.0-45.5]) to the lowest estimate in Kerman (16.0% [95% CI 10.7-21.4]). In the 16 cities studied, 50.9% of the seropositive individuals did not report a history of symptoms suggestive of COVID-19, implying an estimation of 3,902,948 (95% CI 3,537,760-4,256,724) asymptomatic infected individuals. Conclusions: Nearly one in three individuals were exposed to SARS-CoV-2 in the studied cities by March 2021. The seroprevalence increased about two-fold between April, 2020, and March, 2021. © 2022, The Author(s).

Related Docs

View other Related Docs

1. Sars-Cov-2 Antibody Seroprevalence in the General Population and High-Risk Occupational Groups Across 18 Cities in Iran: A Population-Based Cross-Sectional Study, The Lancet Infectious Diseases (2021)

2. Seroepidemiological Study of Novel Coronavirus Disease (Covid-19) in Tehran, Iran, Infection# Epidemiology and Microbiology (2021)

3. Update on Sars-Cov-2 Seroprevalence: Regional and Worldwide, Clinical Microbiology and Infection (2021)

Experts (# of related papers)

View all Related Experts

Hossein Poustchi (3)

Reza Malekzadeh (2)

Style	Citing Format
MLA	Zamani M, et al.. "Seroprevalence of Sars-Cov-2 Antibody Among Urban Iranian Population: Findings From the Second Large Population-Based Cross-Sectional Study." BMC Public Health, vol. 22, no. 1, 2022, pp. -.
APA	Zamani M, Poustchi H, Mohammadi Z, Dalvand S, Sharafkhah M, Motevalian SA, Eslami S, Emami A, Somi MH, Yazdanicharati J, Saki N, Karami M, Najafi F, Mohebbi I, Veisi N, Hormati A, Pourfarzi F, Ghadimi R, Ansarimoghaddam A, ... Malekzadeh R (2022). Seroprevalence of Sars-Cov-2 Antibody Among Urban Iranian Population: Findings From the Second Large Population-Based Cross-Sectional Study. BMC Public Health, 22(1), -.
Chicago	Zamani M, Poustchi H, Mohammadi Z, Dalvand S, Sharafkhah M, Motevalian SA, Eslami S, et al.. "Seroprevalence of Sars-Cov-2 Antibody Among Urban Iranian Population: Findings From the Second Large Population-Based Cross-Sectional Study." BMC Public Health 22, no. 1 (2022): -.
Harvard	Zamani M et al. (2022) 'Seroprevalence of Sars-Cov-2 Antibody Among Urban Iranian Population: Findings From the Second Large Population-Based Cross-Sectional Study', BMC Public Health, 22(1), pp. -.
Vancouver	Zamani M, Poustchi H, Mohammadi Z, Dalvand S, Sharafkhah M, Motevalian SA, et al.. Seroprevalence of Sars-Cov-2 Antibody Among Urban Iranian Population: Findings From the Second Large Population-Based Cross-Sectional Study. BMC Public Health. 2022;22(1):-.
BibTex	@article{ author = {Zamani M and Poustchi H and Mohammadi Z and Dalvand S and Sharafkhah M and Motevalian SA and Eslami S and Emami A and Somi MH and Yazdanicharati J and Saki N and Karami M and Najafi F and Mohebbi I and Veisi N and Hormati A and Pourfarzi F and Ghadimi R and Ansarimoghaddam A and Sharifi H and Roshandel G and Mansourghanaei F and Joukar F and Shayanrad A and Eghtesad S and Niavarani A and Delavari A and Kaveh S and Feizesani A and Markarian M and Shafighian F and Sadjadi A and Darvishian M and Malekzadeh R}, title = {Seroprevalence of Sars-Cov-2 Antibody Among Urban Iranian Population: Findings From the Second Large Population-Based Cross-Sectional Study}, journal = {BMC Public Health}, volume = {22}, number = {1}, pages = {-}, year = {2022} }
RIS	TY - JOUR AU - Zamani M AU - Poustchi H AU - Mohammadi Z AU - Dalvand S AU - Sharafkhah M AU - Motevalian SA AU - Eslami S AU - Emami A AU - Somi MH AU - Yazdanicharati J AU - Saki N AU - Karami M AU - Najafi F AU - Mohebbi I AU - Veisi N AU - Hormati A AU - Pourfarzi F AU - Ghadimi R AU - Ansarimoghaddam A AU - Sharifi H AU - Roshandel G AU - Mansourghanaei F AU - Joukar F AU - Shayanrad A AU - Eghtesad S AU - Niavarani A AU - Delavari A AU - Kaveh S AU - Feizesani A AU - Markarian M AU - Shafighian F AU - Sadjadi A AU - Darvishian M AU - Malekzadeh R TI - Seroprevalence of Sars-Cov-2 Antibody Among Urban Iranian Population: Findings From the Second Large Population-Based Cross-Sectional Study JO - BMC Public Health VL - 22 IS - 1 SP - EP - PY - 2022 ER -

Style

Citing Format

MLA

Zamani M, et al.. "Seroprevalence of Sars-Cov-2 Antibody Among Urban Iranian Population: Findings From the Second Large Population-Based Cross-Sectional Study." BMC Public Health, vol. 22, no. 1, 2022, pp. -.

APA

Zamani M, Poustchi H, Mohammadi Z, Dalvand S, Sharafkhah M, Motevalian SA, Eslami S, Emami A, Somi MH, Yazdanicharati J, Saki N, Karami M, Najafi F, Mohebbi I, Veisi N, Hormati A, Pourfarzi F, Ghadimi R, Ansarimoghaddam A, ... Malekzadeh R (2022). Seroprevalence of Sars-Cov-2 Antibody Among Urban Iranian Population: Findings From the Second Large Population-Based Cross-Sectional Study. BMC Public Health, 22(1), -.

Chicago

Zamani M, Poustchi H, Mohammadi Z, Dalvand S, Sharafkhah M, Motevalian SA, Eslami S, et al.. "Seroprevalence of Sars-Cov-2 Antibody Among Urban Iranian Population: Findings From the Second Large Population-Based Cross-Sectional Study." BMC Public Health 22, no. 1 (2022): -.

Harvard

Zamani M et al. (2022) 'Seroprevalence of Sars-Cov-2 Antibody Among Urban Iranian Population: Findings From the Second Large Population-Based Cross-Sectional Study', BMC Public Health, 22(1), pp. -.

Vancouver

Zamani M, Poustchi H, Mohammadi Z, Dalvand S, Sharafkhah M, Motevalian SA, et al.. Seroprevalence of Sars-Cov-2 Antibody Among Urban Iranian Population: Findings From the Second Large Population-Based Cross-Sectional Study. BMC Public Health. 2022;22(1):-.

BibTex

@article{ author = {Zamani M and Poustchi H and Mohammadi Z and Dalvand S and Sharafkhah M and Motevalian SA and Eslami S and Emami A and Somi MH and Yazdanicharati J and Saki N and Karami M and Najafi F and Mohebbi I and Veisi N and Hormati A and Pourfarzi F and Ghadimi R and Ansarimoghaddam A and Sharifi H and Roshandel G and Mansourghanaei F and Joukar F and Shayanrad A and Eghtesad S and Niavarani A and Delavari A and Kaveh S and Feizesani A and Markarian M and Shafighian F and Sadjadi A and Darvishian M and Malekzadeh R}, title = {Seroprevalence of Sars-Cov-2 Antibody Among Urban Iranian Population: Findings From the Second Large Population-Based Cross-Sectional Study}, journal = {BMC Public Health}, volume = {22}, number = {1}, pages = {-}, year = {2022} }

RIS

TY - JOUR
AU - Zamani M
AU - Poustchi H
AU - Mohammadi Z
AU - Dalvand S
AU - Sharafkhah M
AU - Motevalian SA
AU - Eslami S
AU - Emami A
AU - Somi MH
AU - Yazdanicharati J
AU - Saki N
AU - Karami M
AU - Najafi F
AU - Mohebbi I
AU - Veisi N
AU - Hormati A
AU - Pourfarzi F
AU - Ghadimi R
AU - Ansarimoghaddam A
AU - Sharifi H
AU - Roshandel G
AU - Mansourghanaei F
AU - Joukar F
AU - Shayanrad A
AU - Eghtesad S
AU - Niavarani A
AU - Delavari A
AU - Kaveh S
AU - Feizesani A
AU - Markarian M
AU - Shafighian F
AU - Sadjadi A
AU - Darvishian M
AU - Malekzadeh R
TI - Seroprevalence of Sars-Cov-2 Antibody Among Urban Iranian Population: Findings From the Second Large Population-Based Cross-Sectional Study
JO - BMC Public Health
VL - 22
IS - 1
SP -
EP -
PY - 2022
ER -

Science Communicator Platform

Authors

Abstract